<DOC>
	<DOCNO>NCT00846976</DOCNO>
	<brief_summary>This open label , single-centered treatment protocol design monitor safety patient treat 200 mg daily dose CASODEX . Patient receive CASODEX long physician feel benefit form therapy .</brief_summary>
	<brief_title>Treatment Protocol Monitor Safety 200 mg Dose Bicalutamide Patients With Advanced Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate gland Patients advanced prostate cancer Adult male age 18 year old Normal liver function ( AST &lt; 2 x Upper Limit Normal ) ECOG performance status 4 . Previous history presence another malignancy prostate cancer treat squamous/basal cell carcinoma skin , within last 5 year .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Safety</keyword>
</DOC>